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Abstract 
The application of macromolecules in therapy is frequently hindered by stability and/or 
permeation issues. These limitations have been addressed by the pharmaceutical industry 
through the development of suitable non-injectable drug carriers. In this context, nanoparticles 
have emerged as one of the most exciting tools, due to the increased surface-to-volume ratio, 
which provides an intimate interaction with epithelial surfaces. Nanoparticles further enable the 
encapsulated molecules to retain their biological activity, from the production steps to the final 
release. Chitosan has reached a prominent position as carrier-forming material, as diverse 
methods can be applied to produce nanoparticles using that excipient. These involve either 
hydrophilic or lipophilic environments that generally result in mild conditions or aggressive and 
time-consuming processes, respectively. In this review, a detailed description of methods 
employed to produce chitosan nanocarriers is provided, accompanied by illustrative schemes of 
the procedures. The emphasis is on the variables reported to affect the final properties of the 
vehicles.  
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Introduction 
Many biomolecules, although therapeutically promising, are characterised by a marked instability 
due to inherent physicochemical and biopharmaceutical features that make their administration 
extremely challenging. This is the main reason why parenteral delivery is usually the unique 
option. Being invasive and painful, this route is not easily accepted by patients and frequently 
leads to therapeutic incompliance (Andrade et al. 2011). Finding adequate alternatives has 
become a major scientific challenge and researchers have turned their efforts towards the 
design of suitable drug delivery systems that enable non-invasive mucosal administration, with 
the hope to enhance patients’ compliance and, thus, the therapeutic benefits (Zheng et al. 
2010). These drug delivery carriers should exhibit characteristics that include: capacity for drug 
association, ability to enhance their physicochemical stability and protection of encapsulated 
drugs from carrier production to release. Furthermore, in many cases, carriers are expected to 
regulate the drug release profile, while allowing an intimate contact between molecules and 
mucosal barriers, contributing to their epithelial permeation (Chiellini et al. 2008, Luppi et al. 
2010).  
In this context, polymeric nanoparticles have appeared as promising vehicles because of several 
attractive properties, such as an increased surface-to-volume ratio, which offers high potential 
for macromolecule association (Silva et al. 2007), and the capacity to improve drug absorption. 
The latter either results from the reduction of epithelial resistance to drug transport, or the ability 
to carry the drug across the epithelium (Csaba et al. 2006, Wang et al. 2011a). Nanoparticles 
have also been reported to interact with mucosal epithelial membranes (de la Fuente et al. 
2008a, Maurya et al. 2010), an effect that is maximal for particles of 50 - 500 nm (Jani et al. 
1990, Desai et al. 1996). In addition, nanoparticles are described to permeate epithelia more 
easily than microparticles (Jani et al. 1990, Desai et al. 1996, Alonso 2004, Wang et al. 2011a) 
and, in many cases, they have been shown to provide a controlled release of the encapsulated 
drugs (Nagpal et al. 2010, Malam et al. 2011, Wang et al. 2011a). 
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Chitosan is one of the most commonly used natural polymers in the production of 
nanomedicines, because it displays very attractive characteristics for drug delivery and has 
proved very effective when formulated in a nanoparticulate form. Properties such as its cationic 
character and its solubility in aqueous medium, have been reported as determinants of the 
success of this polysaccharide (Janes et al. 2001, Grenha et al. 2010a). However, its most 
attractive property relies on the ability to adhere to mucosal surfaces (Lehr et al. 1992, Blau et 
al. 2000, das Neves et al. 2011), leading to a prolonged residence time at drug absorption sites 
and enabling higher drug permeation (Takeuchi et al. 2001, Andrade et al. 2011). Chitosan has 
further demonstrated capacity to enhance macromolecules epithelial permeation through 
transient opening of epithelial tight junctions (Schipper et al. 1996, Schipper et al. 1999, Luppi et 
al. 2010). In addition, the polymer is known to be biocompatible and to exhibit very low toxicity 
(Hirano et al. 1988, Andrade et al. 2011), which are two mandatory requisites for drug delivery 
applications. Noticeably, chitosan has been referred to be more efficient at enhancing drug 
uptake when formulated in the nanoparticulate form, as compared to solution (Bowman and 
Leong 2006). Several recent reviews are available addressing the most prominent applications 
of chitosan nanoparticles, reinforcing the potential of these carriers in the biopharmaceutical and 
biomedical fields. Those manuscripts either focus on general drug delivery applications 
(Duceppe and Tabrizian 2010, Nagpal et al. 2010, Park et al. 2010, Chaudury and Das 2011, 
Wang et al. 2011a), delivery of genetic material (Duceppe and Tabrizian 2010, Posadas et al. 
2010, Al-Qadi et al. 2011a, Tiera et al. 2011), or more specific applications, such as cancer 
therapy (Bisht and Maitra 2009, Tan et al. 2009, Park et al. 2010) and molecular imaging 
(Agrawal et al. 2010). A general message that can be taken from all these references is that 
materials and methods used to prepare chitosan vehicles are two major players in the carriers’ 
efficacy (Chiellini et al. 2008).  
Nevertheless, taking into account the promising applications of chitosan reported in the last two 
decades, in many cases related to chitosan nanoparticles, questions arise around the absence 
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of commercially available chitosan-based therapeutic formulations. Some possible explanations 
can be found, but the approval of new excipients is known to be slow due to regulatory hurdles 
to demonstrate their safety for human use (Baldrick 2010). In this context, the Food and Drug 
Administration (FDA) has issued guidance on nonclinical studies needed to develop excipients 
(FDA 2005), in which excipients are considered potentially toxic substances that need to be 
evaluated accordingly. It is also recognised that the enormous variety of chitosan molecules, all 
differing in their molecular weight and deacetylation degree, not to mention in other flexible 
characteristics, poses many difficulties to regulatory agencies, required to perform rigorous 
evaluations (Kean and Tanou 2010). A very recent and complete review on chitosan safety as 
pharmaceutical excipient can be consulted in (Baldrick 2010). 
Owing to the enormous potential demonstrated by chitosan-based nanocarriers, it seemed 
relevant and adequate to describe and compare in the same review, the various methods 
detailed in the literature for the preparation of such useful tools. In addition to providing a 
comprehensive report of the procedures, this review also entails a discussion on the parameters 
affecting the final properties of the vehicles. Many studies can be found on the application of 
chitosan derivatives or the use of chitosan as coating material, but these two approaches are out 
of the scope of the present review. Nevertheless, special emphasis will be placed on the 
secondary materials involved in the carriers’ production. 
 
Methods for the preparation of chitosan nanoparticles 
Chitosan nanoparticles were first described in 1994, when Ohya and coworkers (1994) proposed 
the intravenous delivery of 5-fluorouracil, an anticancer drug, carried by chitosan nanoparticles 
obtained by emulsification and cross-linking. Since then, these systems have been extensively 
studied for drug delivery purposes and the original formulation was either used for other 
applications, such as the incorporation of active substances in toothpastes (Liu et al. 2007a), or 
modified by the application of different preparation methods (Calvo et al. 1997, Erbacher et al. 
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1998, El-Shabouri 2002). In addition, many researchers have developed new formulations of 
chitosan nanoparticles that included secondary matrix-forming materials (Du et al. 2004, 
Sarmento et al. 2006a, Sarmento et al. 2006b, Grenha et al. 2010b). In particular, varied 
methods have been developed, mainly involving emulsification, different types of coacervation, 
or even slight modifications of these. More specifically, the methods include emulsion-droplet 
coalescence (Tokumitsu et al. 1999a), emulsion solvent diffusion (El-Shabouri 2002), reverse 
micellar method (Mitra et al. 2001), ionic gelation, polyelectrolyte complexation (Calvo et al. 
1997, Sarmento et al. 2006a) and desolvation (Tian and Groves 1999), whose particularities will 
be described in the following sections. All these methods comprise bottom-up fabrication 
processes, which involve the assembly of molecules in solution to form defined structures (Chan 
and Kwok 2011), in this case, nanoparticles. Delivery systems resulting from bottom-up 
technologies usually display size polydispersity (Wang et al. 2011b), which in some cases limits 
nanoparticle usefulness. In fact, is it assumed that in a polydisperse system, larger nanoparticles 
might have higher drug loading capacity, while smaller nanoparticles are expected to have 
higher efficiency at delivering drugs to tissues or cells. This means that, even if the drug carrier 
has high encapsulation efficiency, the efficacy of the delivery may be poor (Fan et al. 2012), 
compromising the therapeutic efficacy. Interestingly, a recent technological development related 
to a top-down process termed particle replication in non-wetting templates (PRINT),which is a 
modified soft lithography technique, has demonstrated independent control over nanoparticle 
size, as well as other parameters that include shape, modulus (stiffness) and surface chemistry 
(Canelas et al. 2009, Wang et al. 2011b). Nevertheless, although this technology appears very 
promising in drug delivery, so far, no application was reported for chitosan, even though the 
authors indicate that a wide range of materials can be used, including biodegradable and 
biocompatible polymers (Wang et al 2011b). 
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Table 1 provides summarised information on the methods applied to produce chitosan-based 
nanocarriers, as well as on their matrix composition, and displays a list of secondary materials 
that can be combined with chitosan to form the nanoparticulate systems.  
 
Emulsification and cross-linking 
As mentioned above, this method was the first to be used to form chitosan nanoparticles and 
involves the preparation of a W/O emulsion (this first report described the emulsification of 
chitosan aqueous solution in toluene, using Span 80® as emulsifier), with subsequent addition of 
a cross-linking agent that has the function of hardening the formed droplets. The reactive amino 
groups of chitosan undergo a covalent cross-linking with the aldehyde groups of glutaraldehyde 
(Figure 1), which is added after the emulsion formation and, consequently, after nanoparticle 
production (Ohya et al. 1994). Those authors pioneered the production of chitosan 
nanoparticles, which were used to deliver 5-fluorouracil. Other authors used the method for the 
same purpose of drug delivery, but modified the oil phase composition to liquid paraffin and 
petroleum ether (Songjiang and Lixiang 2009). The final particle size was demonstrated to be 
highly dependent on stirring speed, as well as on the extent of cross-linking (Agnihotri et al. 
2004, Prabaharan and Mano 2005). Several drawbacks have been progressively pointed out for 
this method, including the need of tedious procedures and the application of harsh cross-linking 
agents (Agnihotri et al. 2004). In fact, cross-linkers such as glutaraldehyde were found to cause 
overt toxicity and to compromise drug integrity, contributing to a progressive shift of interest 
towards less aggressive procedures (Janes et al. 2001). Consequently, the application of this 
method to obtain chitosan nanoparticles was restricted to a few works. 
 
Emulsion droplet coalescence 
This method is a derivation of the emulsification and cross-linking method described above and 
was first reported for microparticles preparation (Tokumitsu et al. 1999a). The same authors 
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later adapted the method to prepare chitosan nanoparticles loaded with gadolinium, as a 
strategy for neutron-capture therapy of cancer (Tokumitsu et al. 1999b). Chitosan is dissolved in 
the aqueous solution of gadolinium and a small aliquot (1 mL) of this is added to 10 mL of liquid 
paraffin containing sorbitan sesquiolate (Span® 83). The mixture is stirred with a high-speed 
homogeniser, thus forming an W/O emulsion (Figure 2). In parallel, another W/O emulsion is 
prepared by adding 1.5 mL NaOH to 10 mL of a similar outer phase. Both emulsions are then 
mixed using a high-speed homogeniser, leading to droplet coalescence. This results in the 
solidification of chitosan particles by action of NaOH, which acts as precipitating agent. 
Afterwards, a further set of washing and centrifugation steps is applied using toluene, ethanol 
and water (Tokumitsu et al. 1999b). A similar procedure was used in a different study to 
encapsulate 5-fluorouracil (Anto et al. 2001). This method exploits the fact that, when two 
emulsions with equal outer phase are mixed together, droplets of each collide randomly and 
coalesce, resulting in final droplets with uniform content. The nanoparticles are formed within the 
emulsion-droplets (Ichikawa et al. 2006). Decreasing chitosan deacetylation degree was shown 
to increase particle size and to reduce nanoparticle capacity for drug association, as a 
consequence of the diminished capacity of ion-pair formation and de-swelling (Tokumitsu et al. 
1999b). It was also found that varying chitosan concentration between 0.5 and 2.5% did not 
affect 5-fluorouracil encapsulation efficiency (around 70%) or release profile, which extended 
over 13 hours (Anto et al. 2011). To our knowledge, no other works report the application of this 
method to produce chitosan nanoparticles.  
 
 Emulsion solvent diffusion 
The emulsion solvent diffusion method of preparing chitosan nanoparticles is an adaptation of 
the original procedure developed to produce PLGA-based nanoparticles (Niwa et al. 1993), 
setting its basis on the partial miscibility of an organic solvent with water. The specific method for 
preparation of chitosan nanoparticles involves the addition of an organic phase (e.g. methylene 
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chloride and acetone) containing the hydrophobic drug, to an aqueous solution containing 
chitosan and a stabiliser (e.g. poloxamer and lecithin), under stirring (Figure 3) (El-Shabouri 
2002). This leads to the formation of an O/W emulsion which is then subjected to high pressure 
homogenisation. Methylene chloride is subsequently removed under reduced pressure at room 
temperature. At this stage, acetone diffuses to the aqueous phase, decreasing chitosan solubility 
and, thus, nanoparticles are formed upon polymer precipitation. An additional amount of water is 
usually added in order to permit the complete diffusion of acetone. Finally, nanoparticles are 
isolated by centrifugation.  
This method demonstrated to be suitable for encapsulating hydrophobic drugs like cyclosporin-
A, with high encapsulation efficiencies. In spite of the limited number of studies available on the 
method, parameters such as chitosan molecular weight, homogenisation rate and reaction time 
(period of evaporation and diffusion), are expected to affect the final properties of the vehicles. 
The presence of acetone was also reported as essential (El-Shabouri 2002), since its rapid 
diffusion disturbs the organic/aqueous phase interface, which spontaneously produces a larger 
area and, thus, leads to the formation of much smaller droplets. Particles produced without 
acetone presented sizes outside the submicron range (above 1.2 m).  
Notwithstanding the ability of this method  to produce effective vehicles, it is important to 
highlight the need for harsh preparation conditions, such as organic solvents and high shear 
forces, which are absent in several other methods that will be described in subsequent sections. 
 
Reverse micellisation 
The production of chitosan nanoparticles from reverse micelles was first reported by Mitra et al. 
(2001) as a strategy for tumour targeted delivery. Reverse micelles are W/O droplets and thus 
form in a W/O system (Pileni 2006), in contrast to conventional micelles that form in O/W 
environment. In this method of reverse micellisation, a W/O microemulsion is prepared using a 
lipophilic surfactant that is dissolved in an appropriate organic solvent, like n-hexane. 
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Surfactants like sodium bis(ethyl hexyl) sulfosuccinate (AOT) or cetyl trimethylammonium 
bromide have been used. An aqueous phase comprising chitosan, the drug and glutaraldehyde 
is then added over the organic phase under continuous stirring. As depicted in Figure 4, reverse 
micelles are produced at this stage. Thereafter, nanoparticles are extracted following solvent 
evaporation (Mitra et al. 2001, Banerjee et al. 2002). It is described that an increase in the cross-
linking rate results in the production of larger particles (Banerjee et al. 2002). 
As compared to other emulsion-based methods, the reverse micellisation method has the 
advantage of producing ultrafine nanoparticles of around 100 nm or even less, with a narrower 
size range, in contrast to the larger nanocarriers (> 200 nm) usually obtained by other 
emulsification techniques. Nevertheless, disadvantages such as the difficult isolation of 
nanoparticles and the need for larger amounts of solvent, have been mentioned (Tang et al. 
2007).  
Apart from the application in anticancer therapy, other authors have later used this method as a 
strategy for enzyme immobilisation (Tang et al. 2007) or to encapsulate oligonucleotides 
(Manchanda and Nimesh 2010). 
 
Ionic gelation and Polyelectrolyte complexation 
When chitosan has a high degree of protonation of the amine functions, it displays the capacity 
to form hydrogels in presence of specific polyanions. This process derives from inter- and intra-
molecular cross-linkages mediated by the anionic molecules (Janes et al. 2001, Terbojevich and 
Muzzarelli 2009) and has been used to produce chitosan-based nanoparticles by ionic gelation 
or polyelectrolyte complexation. It should be noted that ionic gelation is the preferred term when 
chitosan gelation is induced by small anionic molecules, such as phosphate, citrate, sulfate, 
while a polyelectrolyte complexation is considered to occur when anionic macromolecules are 
used instead of small molecules (Bhattarai et al. 2010). The latter approach is often referred to 
as complex coacervation or interfacial coacervation (Poncelet 2005, Kissel et al. 2006). 
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Materials applied in the production of such chitosan nanoparticles include polymers such as 
dextran sulfate (Sarmento et al. 2006b), sodium alginate (Sarmento et al. 2006a, Yang et al. 
2011), carrageenan (Grenha et al. 2010b), arabic gum (Avadi et al. 2010), glucomannan (Du et 
al. 2004), carboxymethyl cellulose (Kaihara et al. 2011), chondroitin sulfate (Yeh et al. 2011), 
pectin (Grabnar and Kristl 2010), heparin (Liu et al. 2007b), hyaluronic acid (de la Fuente et al. 
2008b), cyclodextrins (Teijeiro-Osorio et al. 2009), poly-γ-glutamic acid (Lin et al. 2007, Lin et al. 
2008) and  poly(acrylic acid) (Hu et al. 2002), as well as protein-based molecules, like insulin 
(Bayat et al. 2008), or even DNA (Erbacher et al. 1998, Xu et al. 2011). One work reports the 
use of sodium lauryl sulfate (Elsayed et al. 2011). In some cases, both the aforementioned 
methods are combined to form nanoparticles. Examples of these systems include 
chitosan/alginate/tripolyphosphate (Goycoolea et al. 2009), 
chitosan/glucomannan/tripolyphosphate (Alonso-Sande et al. 2006), chitosan/hyaluronic 
acid/tripolyphosphate (de la Fuente et al. 2008b) or chitosan/cyclodextrin/tripolyphosphate 
(Teijeiro-Osorio et al. 2009) nanoparticles. 
Benefiting from chitosan gelation in the presence of anions, Bodmeier et al. (1989) reported the 
production of chitosan beads for oral administration. Calvo et al. (1997) developed a very mild 
adaptation of ionic gelation to prepare chitosan nanoparticles in a complete hydrophilic 
environment. That method involves an ionic interaction between the positively charged amino 
groups of chitosan and the polyanion tripolyphosphate (TPP), which acts as chitosan cross-
linker. Nanoparticles formation takes place immediately after the addition of a TPP solution to a 
solution of chitosan, under mild stirring, at room temperature (Figure 5). Stirring should be 
maintained for approximately 10 minutes to allow particle stabilisation and the obtained 
suspension centrifuged to separate the nanoparticles from unreacted chitosan and TPP. The 
resultant pellet of nanoparticles is then resuspended in water (Carvalho et al. 2009).  
As mentioned above, many different materials have been employed to produce chitosan 
nanoparticles by both methods. The formed nanoparticles were then used to administer different 
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drugs (insulin, bovine serum albumin, polypeptidic mixtures, ovalbumin, tetanus toxoid, estradiol, 
carvacrol, heparin, cyclosporin-A, saponin, epidermal growth factor receptor) through various 
routes of administration (oral, nasal, pulmonary, ocular) (de Campos et al. 2001, Ma et al. 2002, 
Du et al. 2004, Cuña et al. 2006, Sarmento et al. 2007, Wang et al. 2008, Oyarzun-Ampuero et 
al. 2009, Azizi et al. 2010, Grenha et al. 2010b, Keawchaoon and Yoksan 2011, Rejinold et al. 
2011). The author’s experience in the field and other works available in the literature, have 
demonstrated that the final properties of chitosan nanoparticles obtained through electrostatic 
interaction are dependent on several parameters inherent to the preparation method. In this 
sense, controlling the stirring pattern (speed and type of vial, most importantly) and the 
conditions of centrifugation (speed and duration), is of utmost importance (Carvalho et al. 2009), 
independently of the specific materials composing the nanoparticle matrix. Optimising variables 
like materials concentration and mass ratios, as well as temperature of the reacting solutions 
and the volume of resuspension (Calvo et al. 1997, Carvalho et al. 2009, Fan et al. 2012), is also 
an important task. In fact, nanoparticles produced by polyelectrolyte complexation between two 
oppositely charged polymers, undergo a size increase with the incorporation of increasing 
amounts of one of the polymers (Hu et al. 2002, Sarmento et al. 2006b, Teijeiro-Osorio et al. 
2009, Grenha et al. 2010b). In contrast, the production of nanoparticles by ionic gelation results 
in smaller particles for higher amounts of cross-linker (Grenha et al. 2005, Teijeiro-Osorio et al. 
2009). A very recent work on chitosan/TPP nanoparticles has also established that the 
concentration of acetic acid used to dissolve chitosan and the temperature at which the cross-
linking process occurs, strongly affect the polydispersity of the obtained nanoparticles. 
Interestingly, the authors demonstrated that performing the reaction below 4 ºC results in a 
polydispersity index below 0.05. This was attributed to the fact that reduced temperature 
increased hydrogen bonds between the polar groups of chitosan and the surrounding water, 
leading to the formation of a hydration layer around the nanoparticles, which decreased the 
probability of nanoparticle collision. In parallel, a concentration of 0.2 mg/mL of acetic acid was 
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shown to be optimal for achieving a narrow particle size distribution, as it is the concentration 
required to provide sufficient protonation of chitosan for interaction with TPP (Fan et al. 2012). 
In addition, the type of chitosan used has also been reported as crucial. Chitosan exists under 
many different chemical structures, being available either as a base or a salt (different types of 
salts are also available, such as chloride, lactate, glutamate, etc.). Moreover, distinct molecular 
weights and deacetylation degrees also exist. Several studies have established a relation 
between these features and the final characteristics of the resultant chitosan nanoparticles (Xu 
and Du 2003, Huang et al. 2004, Zhang et al. 2004, Al-Qadi et al. 2011b), revealing that 
chitosan structure determines nanoparticles preparation variables, as well as their final 
properties, such as size and zeta potential. The influence of these characteristics on the polymer 
performance in mucosal and transmucosal drug delivery was addressed in a recent review 
(Bonferoni et al. 2009).  
The most important advantage claimed by those working with the methods of ionic gelation and 
polyelectrolyte complexation is the complete hydrophilic environment and the mild preparation 
conditions (Agnihotri et al. 2004). In fact, the avoidance of organic solvents or high shear forces 
makes encapsulation of labile drugs an easier task (Tiyaboonchai 2003) and, possibly for this 
reason, those two methods are the most widely used to produce chitosan nanoparticles. 
Importantly, through physical cross-linking mediated by an electrostatic interaction, instead of a 
chemical cross-linking with glutaraldehyde, those methods of chitosan nanoparticle production 
have  improved cell viability and drug integrity (Janes et al. 2001, Agnihotri et al. 2004). 
 
 
 
Modified ionic gelation with radical polymerisation 
This method is derived from ionic gelation, but introduces a modification, because chitosan 
gelation occurs concomitantly with the polymerisation of acrylic acid monomers. The first step 
occurs at room temperature and consists in stirring an aqueous monomer solution of acrylic or 
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methacrylic acid with an aqueous solution of oppositely charged chitosan. In some cases, 
polyethylene glycol (PEG) or polyether (polethylene glycol-polypropylene glycol-polyethylene 
glycol) are also added to the reaction medium, either separately into the monomer solution or 
following mixing with chitosan. As depicted in Figure 6, the opposite charges of chitosan and 
acrylic or methacrylic acid lead to an ionic interaction, while radical polymerisation of the latter is 
initiated by the addition of potassium persulfate. This reaction takes place under a nitrogen 
stream and the temperature is usually raised to 60 - 70 ºC. The polymerisation reaction lasts for 
approximately 6 h, after which the formed suspension of nanoparticles is allowed to settle 
overnight.  Finally, unreacted monomers are removed by dialysis or subsequent washes of the 
formed particles with distilled water. Nanoparticles obtained by this method have been used to 
administer insulin, bovine serum albumin and silk peptide through the oral route (Hu et al. 2002, 
Sajeesh and Sharma 2006a, Sajeesh and Sharma 2006b). 
Increasing chitosan molecular weight was shown to induce an increase in the molecular weight 
of polyacrylic acid present in the nanoparticles, indicating the occurrence of a template 
polymerization of acrylic acid in the chitosan solution. Parameters such as chitosan/acrylic 
monomers ratio and polymers concentration have been found to strongly affect the 
physicochemical characteristics of the nanoparticles properties. More specifically, it was 
described that the zeta potential increases with the increase in chitosan/acrylic acid ratio, and 
nanoparticles size was smaller for the lowest polymer ratio (1/1) (Hu et al. 2002). 
 
Desolvation 
The method of desolvation is also frequently referred to as simple coacervation or phase 
separation and involves a macromolecular aggregation brought about by partial desolvation of 
fully solvated molecules (Kissel et al. 2006). The use of desolvating agents to produce chitosan 
particles was reported for the first time for the preparation of micron-sized carriers (Berthold et 
al. 1996) but, nowadays, this procedure is frequently applied to the production of chitosan 
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nanoparticles. Substances such as sodium sulfate (Mao et al. 2001, Borges et al. 2005, Atyabi 
et al. 2009) and non-solvents miscible with water, like acetone (Agnihotri and Aminabhavi 2007), 
have been proposed as precipitating agents, although the former has been used more 
frequently. The preparation of chitosan nanoparticles by this method is very simple and mild as it 
involves the dropwise addition of the solvent competing agent of greater hydrophilicity (e.g. 
sodium sulfate) into a previously formed chitosan solution (Figure 7). As the salt enters in 
contact with the aqueous environment of chitosan solution, a progressive elimination of solvation 
water surrounding chitosan occurs as a consequence of the higher affinity of water for the salt. 
Eventually, this process leads to the polymer insolubilisation and its consequent precipitation 
(Alonso 1996, Janes et al. 2001, Poncelet 2005). This effect is observed because water-salt 
interactions are more favourable than those occurring between the water and the polymer, 
inducing the partial desolvation of chitosan. This, in turn, leads to increased interactions between 
chitosan molecules, forming the nanocarriers (Kissel et al. 2006). 
It is very frequent to include a stabiliser such as polysorbate 80 in the preparation medium, to 
stabilise the nanoparticle suspension. A subsequent process of cross-linking, for instance with 
glutaraldehyde, has been described, in order to harden the nanoparticles (Alonso 1996). Factors 
such as chitosan molecular weight, chitosan concentration, amount of desolvating agent and 
stirring rate have been found to strongly affect the final characteristics of nanoparticles. 
Therefore, it is necessary to undergo an optimisation of these parameters. In addition, a 
correlation was identified between the amount of sulphate ions needed and chitosan properties, 
like the molecular weight and the deacetylation degree (Borges et al. 2005). 
 
Conclusion 
Several methods have been developed to produce chitosan nanoparticles, since those have 
been shown to offer attractive advantages as drug delivery carriers. The different production 
methods that were described might result in nanoparticles with distinct properties, including size 
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and charge, which can affect their targeting ability, as well as their capacity for drug 
encapsulation. However, in addition to the preparation method, the final properties of 
nanoparticles also depend on several other parameters like secondary materials composing the 
matrix, material concentrations/ratios and reaction time, amongst others. In addition, the 
available studies report the use of distinct chitosans (molecular weight, deacetylation degree, 
etc.) and varied model/therapeutic molecules. Therefore, in this review, it was not possible to 
compare between the existing methods and conclude on those producing chitosan nanocarriers 
suitable for specific applications, although this would be extremely useful.  
Some of the available methods involve long-lasting and, sometimes, somewhat aggressive 
procedures that limit their application. As a result, some are only reported in a few studies and, 
in such cases, many of the variables that might affect the final nanoparticle characteristics have 
not been thoroughly studied. In contrast, the methods that follow very mild procedures involving 
only hydrophilic environment (mainly polyelectrolyte complexation and ionic gelation), are being 
adopted by the majority of researchers working in the area. In fact, the day-by-day increasing 
amount of work that is based on the application of chitosan nanoparticles has been raising the 
expectation that, in a near future, a chitosan-based nanoparticulate formulation will reach the 
market. As a first step of acceptation of chitosan as excipient, the European Pharmacopeia 
already includes a monograph for chitosan hydrochloride salt and it is known that a monograph 
is in preparation for inclusion in the US Pharmacopeia. 
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Figure captions 
Figure 1 – Schematic representation of the method of emulsification and cross-linking. 
Figure 2 – Schematic representation of the method of emulsion droplet coalescence. 
Figure 3 – Schematic representation of the method of emulsion solvent diffusion. 
Figure 4 – Schematic representation of the method of reverse micellisation. 
Figure 5 – Schematic representation of the method of ionic gelation/polyelectrolyte 
complexation. 
Figure 6 – Schematic representation of the method of modified ionic gelation with radical 
polymerisation. 
Figure 7 – Schematic representation of the method of desolvation with sodium sulfate. 
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Table 1. Methods used for the production of chitosan-based nanoparticles and 
composition of the carriers’ matrix 
 Production Method  Matrix composition Reference 
Emulsification and cross-
linking 
Chitosan, glutaraldehyde (Ohya et al. 1994, 
Songjiang and Lixiang 
2009)  
Emulsion droplet 
coalescence 
Chitosan (Tokumitsu et al. 1999, 
Anto et al. 2011)  
Emulsion solvent diffusion Chitosan (El-Shabouri 2002)  
Reverse micellisation Chitosan, glutaraldehyde (Mitra et al. 2001, 
Banerjee et al. 2002, 
Tang et al. 2007, 
Manchanda and Nimesh 
2010)  
Ionic gelation Chitosan, tripolyphosphate (Calvo et al. 1997, de 
Campos et al. 2001, Ma 
et al. 2002, Wang et al. 
2008; Fan et al. 2012)  
Polyelectrolyte 
complexation 
Chitosan, alginate, arabic 
gum, carboxymethyl 
cellulose, carrageenan, 
chondroitin sulfate, 
cyclodextrins, dextran 
sulfate, polyacrylic acid, 
poly-γ-glutamic acid, insulin, 
DNA 
(Erbacher et al. 1998, Hu 
et al. 2002, Du et al. 
2004, Sarmento et al. 
2006a, Sarmento et al. 
2006b, Lin et al. 2007, 
Bayat et al. 2008, Lin et 
al. 2008, Teijeiro-Osorio 
et al. 2009, Avadi et al. 
2010, Grenha et al. 
2010b, Kaihara et al. 
2011, Yeh et al. 2011)  
Modified ionic gelation 
with radical polymerisation 
Chitosan, acrylic acid, 
methacrylic acid, 
polyethylene glycol, 
polyether 
(Hu et al. 2002, Sajeesh 
and Sharma 2006a, 
Sajeesh and Sharma 
2006b)  
Desolvation Chitosan (Mao et al. 2001, Borges 
et al. 2005, Agnihotri and 
Aminabhavi 2007, 
Atyabi et al. 2009)  
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Schematic representation of the method of emulsification and cross-linking.  
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Schematic representation of the method of emulsion droplet coalescence.  
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Schematic representation of the method of emulsion solvent diffusion.  
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Schematic representation of the method of reverse micellisation.  
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Schematic representation of the method of ionic gelation/polyelectrolyte complexation.  
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Schematic representation of the method of modified ionic gelation with radical polymerisation.  
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Schematic representation of the method of desolvation with sodium sulfate.  
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